Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing in this about RLF related. Racing to get done thru the last minutes? I dont see this as an official PR @ NRXP or on any news outlets? Dug up by a YH poster from their home page.
Not worth an actual PR of course because they PLAN to file on Monday. For Zyemini or RLF-100 collaboration, we will see.
NEWS, The FDA IS Closed. Anyway, only 55k volume @ NRXP up4%.
I dont read Anything about RLF. When will the Fully Processed Data be sent to RLF for their applications at the EMA. Will RLF continue to defer/genuflect to NRXP/JJ? Some time in the future.
Purposeful/Incompetent delays. Animosity or accidently forgot to mention the Patent holder/partnership.
No market left in the USA so NRXP's plan is to infringe on RLF territory?
My tantrum cost 10%, probably more. LOL. Maybe an actual PR Monday/Tuesday. Maybe RLF will be mentioned then.
Pulling near defeat from possible victories. Dr JJ rules...JMHFO...
Except in Oregon. OHSU/OSU/UO...
Really, why did DocW Quit before the Job was done with Ifenprodil?
Four Significant P= values. 5-15 day IL-6 data?..Yea, or 'we sorta see some trends on other stuff'.
Brilliant, 'follow' and invest in Him.
Second path/new path, Buy-Hold-Sell is all investors can do, not Run the Company. We're not even 5% holders or providing a PP. Kibitzing is free speech. At least LS5 backed up his words.
The bloviating continues.
It's the end of May 2021. If and or butt.
AGN is presenting FOUR Significant P=values from the Ifenprodil CT. COVID allowed for a meaningful CT for Ifenprodil. Done.
There is now also a second path being developed by quick CEO decisions, Stroke/DMT.
The past CSO has left the building. JOB INCOMPLETE and or FKtup.
I will buy some more, you do you...GLTA...
Any IP or patents made while employed by AGN stays. He quit, was fired, Deserted. Pathetic action at this time as a CSO during FDA EOP2 presentation. He/NASH was paid Very well. Talk about Flippers. Bashers. Pumpers.
His presentations were pathetic too, especially the Interim, 'kind of a trend' drivel.
Yes, C.M. had to pull the Mic from DocW to reduce the damage to the planned presentations. DocW's babble seemed like he was High and he dressed like a Bum, needed a comb and hair-cut too. JMHFO. Fktup deserter. Maybe follow him. Bye...GLTA...
Will NRXP be handing over exactly the same fully processed Data they are 'in the process of submitting' to the FDA, "immediately"?
I hope for all that the promise of a quick review happens.
When there was no NRX news today of the application and the RLF Meeting news, oh well.
Maybe NRXP does a 'in the process of submitting' Monday, IMO. Further delaying handing over data to RLF? Bonuses for All...
@3.5B+ OS, it wont move big fast, IMO. My LT BE was $.238. Tiger might be right, but <100k interest.?. IDK...
Hate to agree as a resident past pumper but too much Drama and lies and Stupidity and F*ups and apparent Back stabbings.
NRXP/JJ is stealing IMHFO and there will be litigation instead of cooperation. Sad. I'll watch for a while. Probably buy more ***PF. Maybe a ***P flip too...GLTA...
Maybe a mistake under duress but why wait till Friday on a 3 day weekend for a PR about finally doing the EUA application? Waiting on JJ/NRX? WILL there even be a PR?
The application for EUA will take the time for review of data Before any meeting, 4+ weeks. Then after meeting analysis times for any decision of 2-6 weeks. I posted the EOP2 / EOP3 meeting timelines a month ago+ when the application would be filed 'immediately'.
Why no PR about the Swiss and Turkey Inhaler RLF-100 CTs 'start of recruiting'?
By then I may change my mind or there may be litigation or RS news. NRX has split and now have a LTG on their BoDs for show. RLF has a new Patent lawyer.
$25M / 400M more shares?. Quick cash for acquisitions? plus compensation committee work? Very Busy...
...GLTA...
Doc W failed in his work/analysis at the Dec 15 Interim Data fiasco presentation, IMO and that of the PPS. Then he walks out the Backdoor. JOB INCOMPLETE, PPS falls further.
Desertion of us All. Fired I hope. Restricted from dumping all those shares I hope. IF DMT was HIS idea, why leave?
NASH/Doc W were well compensated with expectations of Commitment and Quality CSO work. You're the one that continually posted questions about his commitment of time and other business priorities
I Hope We all still like Ifenprodil and have good expectations for presenting FULL Data at the EOP2 FDA meeting. That would be a CSO presentation.
They will NOW have FOUR points that are Significant P= values to present. IL-6 data was from 5-15 day Data.
The Data, HE as CSO, requested for the CT was collected and compiled. It was HIS JOB to supervise work and interpret POSITIVE Endpoints...NOT say something like, "we see sort of a trend on some other stuff". WTFWTFWTFWTF?
...GLTA...
Opening an Oregun office or establishing some relationships at the High level Universities and research Hospitals makes great sense, IMO.
IMO, #1 is that we are at the waiting stage for possible directions of where Ifenprodil takes us.*
#2>>>A defined second main path of Stroke/DMT-MoU from those (TOUGH) decisions by management, the QUICK work by the New CSO Team, AND They have ALREADY produce these LEGAL Thingees that has enabled AGN grab an important section of this possible market. JMHO.
C.M apparently had the Crews working OT...GLTA...
"Algernon has also filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint Induced Movement Therapy (“CIMT”)."
*Otherwise it's Ben Dover cheep PP time..
Pending litigation will FU both NRXP and RLF, no doubt. A COORDINATED EFFORT to move Aviptadil forward would have been NICE and we COULD have had steady PPS increases. Apparently 'compensation committee' work and raising money for a wider PIPEline took precedence.
They Didn't even Mention the ongoing CTs in the PR.
https://clinicaltrials.gov/ct2/show/NCT04536350?term=aviptadil&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT04844580?term=aviptadil&draw=2&rank=3
NRX is running a couple CTs and RLF has two Inhaler Trials too, Swiss and Turkey. Coordination/cooperation? Apparently NOT. The squabble has also affected NRXp with a declining PPS and dribble volume. Out of nrxp 5-23 and out of here after this BS.
GEM MUST BEEE SOOOO Happpppyyyy. (NOT) I expect liquidity will surely happen and TM's target may occur here.
Completion dates for RLF Inhaler CTs are EOY, leaving plenty of time for Litigations. OMG. Obviously, MY Long hopes for Cooperation or merging for mutual benefit is dimming Fast. Blacked Out?
Even RUMOR of Courts will kill both companies and trash Aviptadil. More DELAYS, WTF.
I was willing to chance a RS for COOPERATIVE EFFORTS, NOT NOW.
Just My Last Humble Fkn Opinions?...GLTA
A combination of RLF, Acer, APR, NRXP may make sense as an actual Pharma. Cooperative Efforts and Logistics...
What does GEM want? Certainly a decent return on their Investments with sufficient liquidity.
+120K @ NRXP with a dropping PPS IS PROBABLY NOT IT...GLTA...
I feel that the USA should re-implement a Draft for a portion of our Military. No sex/college/wealth deferments. Other Public services should be accepted such as Police/Prison Guards/Firefighters/homeless filth clean-up crews. 2 years duty, 21 year olds' required lottery...
With all the long term investing incentives there are sufficient breaks. Those flipping/naked shorts/etc will pay for those activities.
You all must be tired of things like a $750 fed tax paid by many. DT et al.
Foreigners?
Doesn't the implications of the National Debt scare everyone enough? Yep, pay for the Oil wars AND everyone has skin in any future Militaristic decisions.
Yep. we can, at the Least, Pay.
God Blessed our Country so we are obligated to the Past and Future.
JMHFO, Army 72-75...
Well, show me a Micro-Pharma that will present Significant data from their COVID CT on 'Time off ventilator, time in Intensive care, O2 levels and IL-6', to the FDA at their EOP2 meeting in the near future.
Can AGN get approved Endpoints for these indications in a Phase 3 CT.
How can the Ifenprodil CC/IPF CT be changed/incorporated/related to the Covid CT in the future?
The accommodating new Guidelines from the FDA seem encouraging, IMO...
A Glass of Wine and Best Wishes...GLTA...
@.25 or @$2.50 is the SAME, you dont lose anything. Until RLF gets on Nasdaq where there are Institutions and solid investors we will float with that stigma and PPS. Upgrading is the BIG move.
GEM has finally got NRXP, although the deal struggled and at the end JJ didn't deliver. Holding <$25 on low volume.
They (NRXP) will need to work with RLF for some deal to move Zyemini without bringing in lawyers. It's Still the JEWEL and needs cooperative Efforts. IMHFO!!!
Brand names and tweaking patented Formulations for perfection will be Great and help both companies in their respective areas of marketing and Sales.
A Minor change in % of Profits or Area of marketing Cooperation due to easier logistics and manufacturing may be in order, IMO. Profits and Sales of either Zyemini or RLF-100 is basically $0.
A R/s for the huge OS may be supported by GEM. They have the VOTES AND appear to actually care about MONEY... AND GEM PROBABLY HAS PLAN$$$$$ they will ADVISE the MANAGEMENT STAFF OF BOTH NRXP AND RLF about their thoughts/investments...IMHFO...GLTA...
NRXP, Zyemini IV, is making a fizz. TOO BAD most Everyone realizes that the RLF-100 Patent ISSUE is the elephant in the room.
GEM finally got this done and is getting some returns from their long time support of NRX. GEM also is the major financier of RLF and has invested much more there.
Brpa ran to $60+ at the rumor and $40+ last week at the news.
Yes dr JJ sure had the 'rap' but actual reality issues like a PATENT over-rules, IMHO.
I am interested/invested HERE to see what plays out. BRPA HAD to sign NRX TODAY. Will they sell NRX-101 OR IS RLF-100 STILL THE JEWEL? By any Brand name OR Formulation. IV RLF-100!
...GLTA....
BRPA Outstanding shares, 2.69M. 72% held by insiders...Volume 2.8M...?
Virtual meeting and Vote on NRXP, 5-24?
last chance @ +$35? Time to move?
or...
Does NRX have the Cards (Rights/Patent/?Bluff?) May be Tied up in a Court?
NRX-101? LOL!
GEM has a big say in NRX, GEM has much more invested in RLF.
JJ Greed may = ? IS NRXP worth $2.6B?
Thoughts I didn't post earlier...
NRX claims trademarks in this Registration.
"TRADEMARKS, TRADE NAMES AND SERVICE MARKS
BRPA," NeuroRx and their respective subsidiaries own or have rights to, and NRX Pharmaceuticals will own or have rights to, trademarks, trade names and service marks, including ZYESAMI and RLF-100, that they use in connection with the operation of their business."
The Phase 2b/3 Trial was for RLF-100 in the IV Formulation.
The Inhaler versions of NRX and RLF are both Phase 2.
RLF Must have seen this fromNRX. Also why mention the of delay in a EUA application to BRPA voting shareholders? Is it Vote YES 5-24 or lose the deal? VIRTUALY VOTE?
"This product candidate has not yet been submitted for approval and has not yet been approved by the U.S. Food and Drug Administration (“FDA”)."
NRX is saying PAY then we May deliver to BRPA? What about DATA?
RLF needs to Pay for unneeded Formulation tweaking or development from NRX?
RLF-100, Patented, IS the Drug approved for the 2b/3 Clinical Trial. NRX shysters will lose $$150M for $4M?
GEM has a LOT more Inve$ted in RLF than they do in NRX. Basically supporting Both companies. Something will be settled ASAP, IMO.
Max for NRXP deal is $35 from BRPA? Min $10? $0?. BRPA closed@ $34...GLTA...
https://ih.advfn.com/stock-market/NASDAQ/big-rock-partners-acquis-BRPA/stock-news/85169110/registration-statement-for-securities-to-be-issued#D56937DS4A_HTM_ROM56937_2
Seems like the crowd is pushing this past what the Registration says. The deal seems maxed @ $35? As wolf said, yea?
Seems to show their attempt to steal RLF-100 but the EUA must be for the IV formulation. Just the Brand name was changed yet the CT 's 196 patients' DATA is IV. They will have to settle that or contest it.
All IMH,FU,Os...GLTA...
I see RLF-100 finally mentioned. Yes RLF had the 'right' to fund further formulations but I think Rod is sticking with the IV RLF-100 FORMULATION THAT WAS USED DURING THE PHASE 2B/3 CT.
THE INHALERS are in Phase 2 CTs. New formulations will need Trial.
IMO it's GEM trying to kick the mule and dangle more carrots to these shysters'. Its a deal by 5-24 or?
Max set @$35 for BRPA deal? Minimum is $10. NRX-101, LOL. Sold my few brpa.
BUTTTT!
On September 21, 2020, NeuroRx announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of RLF-100 (aviptadil acetate) (now reformulated as ZYESAMITM), an FDA Fast Track-designated, investigational, precommercial drug for COVID-19 related respiratory failure (the “NeuroRx COVID-19 Drug”). The partnership affords Relief Therapeutics the right to fund all formulations and clinical development of aviptadil for treatment of respiratory disease, in exchange for a predetermined share of profits. See the section titled “Business of NeuroRx — Summary of NeuroRx Material In-licensing Obligations — Aviptadil/ZYESAMI — Binding Collaboration Agreement with Relief Therapeutics — Division of Profits” for more information. NeuroRx is also developing NRX-100/101, an FDA Breakthrough Therapy-designated, investigational, precommercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior (the “NeuroRx Antidepressant Drug Regimen”).
https://ih.advfn.com/stock-market/NASDAQ/big-rock-partners-acquis-BRPA/stock-news/85169110/registration-statement-for-securities-to-be-issued
Completing the CT during COVID was tough and probably why their attempts to apply for EUA from Interim data. That was Reasonable attempt to expedite things, but the FDA... Expanding to 196 patients must have been tough also. That all is 'successful' history now with the CT being completed.
The FDA was busy granting BP apps even with incomplete data and Safety issues. $ was talking louder, IMO.
It seems the cooperative efforts of NRX/RLf have provided enough Data Now to make a Strong application. Certainly it's time to pass ALL Completed Data and reviews to RLF and move forward on EMA applications.
I would say RLF/NRX has completed the Newest FDA guidance for the RLF-100 IV formulation that the CT was designed for. The new formulations of RLF-100 for Inhalers and extended shelf life may be affected by the posted FDA Guidance as they move forward from Phase 2.
Acer may also benefit, IMO.
https://finance.yahoo.com/news/acer-therapeutics-reports-q1-2021-200100894.html
Maybe the new FDA guidelines would allow a change in Trial design to include other Countries besides just the USA to Expedite the Buc CT.?. Plenty of COVID patients in so many other Countries.
Brazil/Turkey/India.
The USA is Finally not #1 for 'critical/hospitalized' patients any more...GLTA...
https://www.fda.gov/media/148739/download
Some new stuff from the FDA.
Would AGN's EOP2 meeting for guidance on the Phase 3 design or endpoints be involved?
It seems the Ifenprodil CT covered most of this guidance already.
Maybe this gives AGN latitude to participate in a Sponsor's 'Master protocol' and it also may make it easier for a BP to incorporate Ifenprodil into a 'cocktail' approach.?.
Sure seems like there is still Strong support from the FDA for COVID drug Clinical Trials. At the least...GLTA...
https://www.fda.gov/media/148739/download
NRX has No shame. They have BRPA over a barrel yet have NOT delt with the holders of the RLF-100 patent. What will they do with the additional shares?
GEM will vote Yes on this and More to secure their investments, IMO...GLTA...
Proposal No. 2 — The Charter Proposals — to consider and vote upon separate proposals to approve amendments to BRPA’s amended and restated certificate of incorporation (“Charter”), which amendments will be effective following the consummation of the Transactions and will be embodied in a second amended and restated certificate of incorporation of BRPA (the “Proposed Charter”), to: (i) change the name of BRPA from “Big Rock Partners Acquisition Corp.” to “NRX Pharmaceuticals, Inc.”; (ii) increase the number of authorized shares of Common Stock from 100,000,000 shares to 500,000,000 shares; (iii) increase the authorized shares of preferred stock from 1,000,000 to 50,000,000, (iv) require an affirmative vote of holders of at least two-thirds (66 2/3%) of the voting power of all of the then outstanding shares of voting stock of NRX Pharmaceuticals following the consummation of the Transactions, voting together as a single class, to amend, alter, repeal or rescind certain provisions of the Proposed Charter relating to the authorization and issuance of preferred stock, the board of directors, stockholder actions, liability of directors, indemnification of directors and officers, forum selection and amendments to the Proposed Charter, (v) provide for the removal of directors with cause only by stockholders voting at least three-quarters (75%) of the voting power of all of the then outstanding shares of voting stock of NRX Pharmaceuticals entitled to vote at an election of directors, and (vi) remove the various provisions applicable only to special purpose acquisition companies that will no longer be applicable to BRPA after the consummation of the Transactions — we refer to these proposals as the “charter proposals”;
https://ih.advfn.com/stock-market/NASDAQ/big-rock-partners-acquis-BRPA/stock-news/85115030/filing-of-certain-prospectuses-and-communications
The statisticians don't evaluate the date, just compile it. IMO, Dr. M Williams was Fired. With Cause.
Tell us about one CSO presentation that MW didn't flub when CM passed the mick to him. The prime date to present a positive review of the supplied statistics was DEC-15-2020.
All other LATER comments were/ARE STILL fire control attempts.
We finally have significant Data to present at an EOP2 FDA meeting. I'm invested in the prospects of Ifenprodil. 5 day Data of IL-6 released in MAY!
Slipped out the back Jack / he messed up THE Big Chance Lance...GLTA...
Mark Williams was well rewarded to get things Right. So were The BOD and CM that followed that advice. CM got the Private Placements to initiate them. They convinced them and us shareholders too, because we all believe in Ifenprodil science. I still do or why be here.
IMO AGN is just now Attempting to UNDO the Damage Dr M Williams did by being too Dumb a Scientist to correctly evaluate the Interim AND FINAL Data. The Scientific failures were only surpassed by the dismal Presentations by the CSO.
Yes, CM and the BOD brought in a different team for the 'International' 2b/3 Trial, Right? Dr.MW was busy elsewhere as you pointed out.
Just reported 5 day IL-6 data. WTF?...
Dr. MW (NASH) got 40% of AGN and a paycheck to get it Right. Dr. MW is the only one that got rich quick. I hope he is not allowed to dump his shares.
The possible Positive future that AGN has is the BETTER evaluations and documentation of the COVID CT that will be presented to the FDA during the EOP2 meeting.
Dr. Mark Williams is who I meant. It certainly made my last posts more confusing. Please Excuse my chemo brain about the CW=MW thingee.
My point is that it was HIS responsibility for the IPF/CC and S.K. Covid Trial plans and subsequent flops/failures. A Chief Science Officer vs CEO. Yes CM signed off. As we all did, especially the ones following an investment since BTH - pre(-40%) Nash.
Dr. Mark Williams flubbed the Dec 15 presentation and Failed in HIS job to extract and interpret the Positive data that is now seen. "We see Sort of Trends"? WTF? THAT is Caused our current problems, IM Hind-sighted FO.
The current Science Team HAS found Significant Data Missed by Dr. MW. A CEO usually doesn't discuss the company's efforts until they become material events.*. I think it would a Very Stupid thing to 'Fire them all" before we see where the EOP2 Meeting takes us...
*or some even After they're done.
Dr. Mark Williams = Flakley Foont.
It would be logical for RVV to partner long term or even sell their Buc 'Rights' when/if the Data is good. That's one of the reasons we are here, I guess. R vs R...
Full logistics and sales would be a big task.
A little more info about EMA Therapeutics at about minute 15 +-.
At least 3 approved for use by Sept and 2 more by the end of the year. The only one currently made available is Rem...GLTA...
Brilliant guys, fire the CEO and center of any continuity Before things play out with the EOP2 FDA Meeting and where there is a chance for something truly positive. Certainly harass him on the phone and take up a few hours of time making him into a PR guy.
Blame Dr CW for HIS INEPT reading of the Interim data. Something Positive at that point would have changed the current course but instead we got Dr CW's disastrous presentation on De 15. Yes, he found Ifenprodil but HE Fkt up the IPF/CC Trial in Australia and then SKorea.
CM wasn't the Science officer or responsible for those Trial plans. CW got 40% of whatever plus a paycheck...
Shareholders can Buy, Hold, Sell, Flip. A portion of Wine is fine. BUTT?
...GLTA...
Well thanks for your opinion. My post was to provide the link to the MB in general'
CW brought in Novatech and ran the AUS/NZ IPF/CC failures and then the SK mess. Our current Science Team ran the COVID Trial (mostly) which is NOW showing results that the Past Science officer barely called 'Trends' at the Interim data release. P=<.04/.03/.01. WTF?
It was His * time to provide positive encouragement of the Ifenprodil Trial Results for AGN and Shareholders, but apparently his mind was busy elsewhere.
*CW=Flakley Foont, IMO.
AGN is now picking up the pieces of these presentations regarding the COVID Trial results and is finally giving the CEO some better cards. I am again willing to see what plays out. (ie at a 25%+ discount)
The association of IPF/CC with the COVID Ifenprodil results is pretty important, IMO.
Maybe some folks tolerance of AGN has waned. Maybe take a break or move on to reduce stress. Get laid. Get tiny. It's a "Speculative OTC" investment. I wouldn't sell now, it's time to BUY, IMHFO! ...GLTA...
New interview tying together IL-6 - IPF - COVID data...
Good to hear about progress with Ifenprodil.
They Probably will discuss the Trial results of O2 levels, reduced time in Intensive care and now IL-6.
!!
The FDA apparently expects some proposals and Data to review...
Some one posted the expected timelines of the EOP2 process.
Only Elli/Pfe/JJ/Gil/ Big Pharmas can pay to jump the line, even with inferior results.
I expect CM and our Trial team to continue their work towards the EOP2 meeting.
Given the possibilities I have Traded to my benefit. IF I/WE win...GLTA...
BTW, did we ever do anything Nash. CW=Flakley Foont.
I had an OIC that shot himself in the knee/foot trying to quick draw his .45...
The whole thing is a Funny long story, sort of. Created lots of extra issues.
Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Ifenprodil-Reduced-Interleukin-6-in-Phase-2b3-COVID-Study?id=302487
With the research and detail of some posters, it would seem reasonable to assume they could possibly TRADE towards a better financial position in this stock. This is still an OTC speculative stock representing a small company. Many have long histories here on which to make informed decisions.
OAN, we should be seeing some presentations from the company regarding the latest IL-6 results and their significance...GLTA...
Thanks Shell for posting this Very relevant info from AGN.
This may be the basis for an Endpoint in a possible Phase 3 CT. I would guess CEO CM now has another Card in his hand.
Looks to me like there are Increasing possibilities of attracting a partner.
Too bad we chased off some of the Drs that posted here. I would appreciate more opinions on what this may mean...GLTA...
The Clinical Trial was for RLF-100 in the Frozen IV form. The CONTRACTS were written for the RLF-100 IV frozen formulation and all future formulations.. RELIEF owns that patent...
IMO, ANY attempts at changes or make upgrades to the Drug is OUTSIDE the Original Contracts. Negotiating Contracts regarding the Inhaled Formulation should be / are separate.
EMA and FDA applications are/will be for RLF-100 in that specific Frozen formulation. EUA s will be Granted for the Frozen Formulation. The Inhaled Formulation and any subsequent 'long shelf life' Formulations are Separate.
The USA market for COVID has dried up temporarily and NRX is using a Public opinion campaign to try for a larger part of the 'Rest of WORLD' Markets where COVID is in successive waves.
Truly disgusting of the "famous" dr JJ to PUBLICALLY delay the progress already achieved success with the IV Clinical Trial for a few questionable %...JMHFO...
Very important that Aviptadil is the only possible finalist that is NOT a MAb. Just on that basis the EMA may include it, IMO.
Aviptadil will be less expensive and works.
"You Know."
Excellent DD by the Author, IMO.
https://www.reddit.com/r/ReliefTherapeutics/comments/n744kw/brparelief_therapeutics_is_almost_certainly_to_be/
BTW I noticed BRPA/NRX/RLF were the combined 'Headline'. NRLAAA...GLTA...
That is a heavy list of EU drug companies (even AZ) when looking at the whole group that were considered. *
WOW, Aviptadil in Finals. Pretty GREAT article, Thanks...
* List link in that article.
I too have been following the EMA since getting info from Dutch relatives about the differences Most Europeans Now feel toward the FDA/USA handling of our pandemic/crisis(s). (DT foreign policies).
...GLTA...
"Additionally, AT7519 and ifenprodil, which showed slightly lower vRNA level reduction, were included because of their distinct binding sites outside of the active site. From these 11, seven compounds (AT7519, calpeptin, ifenprodil, MUT056399, pelitinib, tolperisone, and triglycidyl isocyanurate) exhibited a ≥100-fold reduction in infectious particles in combination with either a selectivity index [SI; calculated as the 50% cytotoxic concentration (CC50) divided by the EC50] of >5 or no cytotoxicity in the tested concentration range and are considered antivirally active (table S5)."
https://science.sciencemag.org/content/372/6542/642